Certmedica International

What Certmedica International does

Certmedica International GmbH is a privately held, medium-sized German medical device company headquartered in Aschaffenburg, specializing in certified healthcare products built around a proprietary active ingredient called polyglucosamine L112. The company develops, manufactures, and distributes globally across four therapeutic areas: overweight and obesity, dry mouth and oral health, women's health, and metabolic syndrome and longevity. Its core commercial products are the formoline L112 weight-management medical device line (including the formoline L112 EXTRA extension positioned as an option beyond GLP-1 therapies) and the aldiamed range for dry mouth and oral health.

The underlying technology platform is polyglucosamine L112, described by the company as a multifaceted "diamond" that anchors a clinical pipeline and supports differentiated claims across indications. Manufacturing and quality systems operate under ISO 13485, EU MDR certifications (G70 and G12), GDP, and a German wholesale permit (Großhandelserlaubnis), with Summary of Safety and Clinical Performance documentation published in 20+ European languages. The business is sold through retail pharmacies (OTC and prescription), dedicated brand e-commerce sites (formoline.de, aldiamed.de), and a B2B expert portal targeting physicians and pharmacists, combining a consumer pull motion with HCP-driven recommendation channels across 17+ EMEA markets. Leadership sits with Ralf Domdey as Managing Director; the company is self-funded with no disclosed external investors, parent company, or acquisition history.

Name

Certmedica International

Legal name

Certmedica International GmbH

Website

https://certmedica.com

Company type

Private

Operating status

Operating

Headcount range

51–100 employees

Short description

Certmedica International GmbH is a privately held German medical device company that develops, manufactures, and distributes certified polyglucosamine L112-based products (formoline L112 weight management line and aldiamed oral health range) through pharmacies, e-commerce, and a dedicated HCP expert portal across 17+ EMEA countries.

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests) (CRADAMAK)

akta.pro secondary industry

Weight Management & Metabolic Supplements (CRADAGAG)

Keywords

• Weight management devices
• Polyglucosamine medical devices
• Obesity treatment devices
• Oral health products
• Certified medical devices

Headquarters

HQ city

Aschaffenburg

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Development, manufacturing, and global distribution of certified medical devices and healthcare products including formoline L112, formoline L112 EXTRA, and aldiamed product range. Revenue generated through product sales to healthcare professionals and consumers via retail pharmacies.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Certmedica International develops, manufactures, and globally distributes certified medical devices and healthcare products based on its proprietary polyglucosamine L112 active ingredient. The portfolio targets overweight and obesity (formoline L112 and formoline L112 EXTRA), dry mouth and oral health (aldiamed), women's health, and metabolic syndrome and longevity. Products are sold through retail pharmacies, dedicated brand websites, and healthcare-professional channels across EMEA.

Product overview

Certmedica International is a medium-sized German pharmaceutical company that develops and markets certified polyglucosamine-based medical devices and healthcare products. The core technology centers on the proprietary active ingredient polyglucosamine L112, which forms the foundation of their product portfolio. Their offerings include formoline L112 and formoline L112 EXTRA for weight management and obesity treatment, as well as the aldiamed product range for dry mouth and oral health. The company operates globally across four therapeutic areas: overweight & obesity, dry mouth & oral health, women's health, and metabolic syndrome & longevity.

Differentiator

Problem solved

Functional benefit

Brands

• formoline L112: Polyglucosamine product line for weight management; includes formoline L112 and formoline L112 EXTRA
• aldiamed

Products and services

• Polyglucosamine L112 Proprietary polyglucosamine compound developed and patented by Certmedica as the core active ingredient underlying its certified medical-device products for overweight and obesity, metabolic syndrome, and longevity.
• formoline L112 Polyglucosamine L112-based certified medical device for weight management and the treatment of overweight and obesity, distributed through retail pharmacies, the formoline.de brand website, and healthcare-professional channels.
• formoline L112 EXTRA Enhanced polyglucosamine L112 medical device formulation targeted at physicians and pharmacists as a non-GLP-1 weight-management option, supported via the Certmedica expert portal with training, offers, and informational materials.
• aldiamed Certified medical-device and healthcare product range for dry mouth symptoms and oral health conditions, distributed through retail pharmacies, the aldiamed.de brand website, and healthcare-professional channels.

Segments5 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators3 records

Recent moves1 record

Expansion highlights4 records

Broad incumbents

• Nestlé Health Science: Nestlé Health Science markets Optifast and other medical nutrition/weight management solutions sold through pharmacies and clinicians in Europe. It competes with Certmedica for physician recommendation and pharmacy shelf space in the same metabolic-health category.
• Novo Nordisk: Novo Nordisk's Wegovy and Saxenda set the dominant standard in obesity treatment and define the GLP-1 competitive threat that Certmedica explicitly references in its 'Beyond GLP-1' messaging. It shapes the market Certmedica must position within.
• Medifast: Medifast is a broader weight-management program operator with physician-recommended meal replacement protocols. It overlaps with Certmedica's overweight & obesity therapeutic area targeting the same health-conscious consumer segment.
• Colgate-Palmolive: Colgate-Palmolive markets dry-mouth and oral care product lines that directly compete with Certmedica's aldiamed franchise for pharmacy shelf space and consumer awareness in the same European oral health category.
• Herbalife Nutrition: Herbalife sells weight-management meal replacement and supplement products globally through direct selling and pharmacy-adjacent channels, competing for the same consumer spending pool Certmedica targets with formoline L112.
• Church & Dwight: Church & Dwight markets oral care products including dry-mouth solutions (Biotène competitor) and other consumer health OTC products. It competes with Certmedica's aldiamed line and adjacent weight-management consumer health products in European retail channels.
• GlaxoSmithKline Consumer Healthcare: GSK markets alli (orlistat), the leading OTC weight-loss pharmaceutical product, and Biotène for dry-mouth oral care — both directly overlapping with Certmedica's formoline and aldiamed franchises in the same European pharmacy channel.

Emerging players

• Allurion Technologies: Allurion markets a swallowable, procedure-less gastric balloon system for weight loss. Although delivery mechanism differs, it competes for the same 'non-surgical, non-pharmaceutical' positioning versus GLP-1 drugs that Certmedica is building with formoline L112 EXTRA.
• Gelesis (Plenity): Gelesis developed Plenity, an FDA-cleared hydrogel oral medical device for weight management. It is a direct product-category comparable — a non-pharmaceutical, oral, certified medical device competing for the same prescriber and consumer weight-loss audience as formoline L112.
• InQpharm Group: InQpharm develops Litramine, a fiber-based fat-binding ingredient used in OTC weight management medical devices and supplements. It is the closest mechanistic comparable to Certmedica's polyglucosamine L112 fat-binding approach, serving similar European pharmacy and DTC channels for weight management.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/certmedica-international-gmbh

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Certmedica International